ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Navigates Growth Amidst Q1 Earnings Miss and Revenue Beat

Font: Financial Modeling Prep  • May 15, 2026

• ARS Pharmaceuticals reported a wider-than-expected quarterly loss of $0.61 per share but exceeded revenue forecasts with $22.68 million, primarily due to strong neffy sales.
• Despite a negative price-to-earnings (P/E) ratio of -3.79 indicating current unprofitability, ARS Pharmaceuticals demonstrates strong financial health with a current ratio of 4.94.
• The company is actively pursuing growth through an expanded sales force, a pending partnership with CVS Caremark, and anticipated clinical study results in Q4 2026, highlighting its commitment to allergy treatment innovation.

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) is a leading pharmaceutical company focused on allergy treatments and biotech innovation. Its flagship product is `neffy`, the first needle-free epinephrine nasal spray. The U.S. FDA and the European Commission have approved `neffy` for treating severe Type I allergic reactions, offering a crucial alternative to traditional injections in the allergy management landscape.

Before the market opened on May 15, 2026, ARS Pharmaceuticals released its latest biotech earnings report. The company reported a quarterly loss of $0.61 per share. This earnings per share figure missed the analyst consensus estimate of a $0.53 loss per share. The loss also increased from the same period a year ago, which was $0.35 per share, indicating a wider EPS miss for the period.

On a more positive note for SPRY stock performance, the company's revenue came in at $22.68 million. This result surpassed the consensus estimate of $22.20 million and shows a large increase from the $7.97 million reported in the year-ago quarter. As highlighted by GlobeNewswire, U.S. sales of `neffy` contributed $17.50 million to this total, showcasing strong product adoption and a significant revenue beat.

ARS Pharmaceuticals' financial metrics provide key investment insights into a company in a growth phase. Its price-to-earnings (P/E) ratio is -3.79, which indicates the company is not currently profitable. However, its current ratio of 4.94 suggests it has a strong ability to cover its short-term financial obligations, reflecting a robust financial health position.

To support its growth strategy and pharmaceutical market expansion, ARS Pharmaceuticals has expanded its sales force to 148 representatives. The company also reports that a proposal with CVS Caremark is in its final approval stages, with an update expected in early June. Additionally, a clinical study readout is on track for the fourth quarter of 2026, further underscoring the company's commitment to future development and market penetration.